https://www.selleckchem.com/pr....oducts/nedisertib.ht
PURPOSE The study aims to assess the visual outcomes of pseudophakic cystoid macular oedema (CMO) as compared to age- and co-pathology matched controls, the costs of treatment and follow up, as well as the patient reported outcomes using the novel Cat-PROM5 questionnaire. SETTING West Suffolk NHS Foundation Trust, UK DESIGN Matched Case-Control Study METHODS 52 eyes of 49 patients developed CMO over an 18-month period. Age and co-pathology matched patients were identified from clinical records over the same time period in a 21 ratio